Nordic Bioscience specializes in precision medicine using the unique Protein Fingerprint biomarkers. By combining our biomarker technologies with our expertise in preclinical and clinical research, we can identify drug candidates through specialized biomarkers. The identification of predictive and prognostic biomarkers enriches clinical trials, which can reduce trial length and size of studies required to determine therapeutic efficacy. Our approach is highly scientific, and we are proud to publish our results frequently in leading journals worldwide. Welcome to the Biomarker Powerhouse!
Three Lakes Foundation
Three Lakes Foundation is a nonprofit dedicated to serving as a catalyst for uniting research, industries and philanthropy in pulmonary fibrosis. We connect entrepreneurs, advocates and institutions to an innovation ecosystem that will transform our approach to improve time to diagnosis and accelerate new therapies.
Xylyx Bio is a New Yorkbased biotechnology company that specializes
in sourcing, characterizing, and developing tissue-specific extracellular matrix (ECM) biomaterials for preclinical applications. Our IN MATRICO® approach is leading the paradigm shift towards more biologically-relevant models to improve decision making in early-stage drug development. Our proprietary platform incorporates minimallyprocessed, human-derived, normal and diseased ECMs that enable scientists to recapitulate essential features of fibrotic diseases, gain insights into the complex interactions between cells and their microenvironment, and improve the translation of antifibrotic drug candidates within clinically-relevant assays.
Labcorp Drug Development
Labcorp Drug Development (formerly Covance) is a leading clinical research organization that provides pharmaceutical and biotech clients with vital information to accelerate innovations and improve patient health through our unparalleled drug development capabilities. Learn more about Labcorp Drug Development at www.drugdevelopment.labcorp.com or follow us on LinkedIn and Twitter @LabcorpDrugDev.
Vitalograph provides sponsors with everything needed to collect, QC, and report on Respiratory endpoint data for the following assessments: FEV1, FVC, SVC, PEF, ECG, ePRO/ eCOA, FeNO, DLCO, 6MWT, and objective cough counting.” Our knowledgeable and responsive teams of dedicated project and data managers, clinical respiratory physiologists, cough analysts, software development engineers, in-house QA and logistic specialists, plus highly-experienced site support staff, are what make our innovative and personalized solutions possible
IPST’s tradition of collaboration and innovation has led to success through association, a foot planted in scientific discovery, the other in the reality of drug development. By combining functional readouts with biomarkers and histology, IPST’s fibrosis models, with pulmonary fibrosis at the forefront, have successfully supported preclinical and clinical candidates for almost a decade.
Owlstone Medical’s mission is to save 100,000 lives and $1.5 billion in healthcare costs by breath-based diagnostics, through the development and application of Breath Biopsy®. Breath Biopsy operates by detecting volatile organic compounds (VOCs) produced as the end product of metabolic processes within the body or as a result of chemicals from external sources such as diet or medication, changes in which can be characteristic of specific disease or indicate environmental exposure.
Rules Based Medicine
Rules-Based Medicine, a Q2 Solutions Company, is a CLIA certified, multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services. RBM’s internally developed and manufactured immunoassays based on Multi-Analyte Profiling (MAP) and Single-Molecule Array (SimoaTM) ultrasensitive immunoassay technology, provide reproducible and quantitative data for hundreds of human proteins.
Aragen is a world leader in accelerating preclinical respiratory disease and fibrosis research. With over 600 fibrosis focused studies under our belt, our strengths lie in translational in vivo modelling of a variety of fibrotic diseases including pulmonary fibrosis. We have combined our strength in IPF with our strength in infectious diseases to help understand potential links between IPF and infectious respiratory diseases. We have perfected the measurement of parameters such as flexiVent™; whole-body plethysmography; and hypoxia related parameters in our animal models and have supported these measurements with a broad suite of biomarkers of respiratory pathophysiology, disease progression, and treatment. Over the years, Aragen has supported the development of multiple modalities (small molecule, large molecule, exosome, RNA therapies) to combat IPF and other fibrosis related indications.
Qureight is a technology company based in Cambridge, UK, which focuses on extracting value from data in complex diseases. Founded in 2018, it was envisioned by a Pulmonologist and a Radiologist based at one of the largest specialist heart and lung hospitals in Europe.
Qureight has developed a proprietary platform techology (driven by the Clarity engine) to structure complex clinical data from patients, both in clinical trials and from healthcare settings. These data inputs can be ingested as multiple sources and typically include images (e.g. chest CT scans), physiology parameters (e.g. pulmonary function measurements) and target-engaged biomarkers. Interpreting these data facilitates a highly controlled and accurate clinical or therapeutic performance readout.